Cefuroxime Dosing for Moderate Community-Acquired Pneumonia
For an adult with moderate community-acquired pneumonia, administer cefuroxime 750 mg IV every 8 hours for 5-10 days, combined with a macrolide (azithromycin 500 mg daily or clarithromycin 500 mg twice daily). 1
Standard Dosing Regimen
The FDA-approved dosing for uncomplicated pneumonia is straightforward:
- 750 mg IV every 8 hours for 5-10 days 1
- This achieves therapeutic serum concentrations of approximately 2 mcg/mL or more maintained for 5.3 hours after each dose 1
- Peak serum concentration after 750 mg IM is approximately 27 mcg/mL 1
Important caveat: Current guidelines do NOT recommend cefuroxime as monotherapy for CAP. The 2019 ATS/IDSA guidelines specify beta-lactam options as ampicillin-sulbactam, cefotaxime, ceftriaxone, or ceftaroline—not cefuroxime—combined with a macrolide for hospitalized patients with moderate CAP 2. However, if cefuroxime is being used, it must be combined with macrolide coverage.
Sequential IV-to-Oral Therapy
A cost-effective alternative after clinical stabilization:
- Start with cefuroxime 750 mg IV every 8 hours for 3-5 days 3, 4
- Switch to cefuroxime axetil 500 mg PO twice daily to complete 7-10 days total therapy 5, 3, 4
- Switch criteria: improvement in all signs/symptoms of pneumonia, ability to take oral medications 4
- This sequential approach shows equivalent efficacy (79-84% cure rates) with significantly lower costs 5, 4
Renal Dose Adjustments
Dose reduction is mandatory in renal impairment because cefuroxime is 89% renally excreted 1:
| Creatinine Clearance | Dose | Frequency |
|---|---|---|
| >20 mL/min | 750 mg - 1.5 g | Every 8 hours |
| 10-20 mL/min | 750 mg | Every 12 hours |
| <10 mL/min | 750 mg | Every 24 hours |
For hemodialysis patients: Give an additional 750 mg dose at the end of each dialysis session 1
Calculating Creatinine Clearance
When only serum creatinine is available 1:
- Males: CrCl = [Weight (kg) × (140 - age)] ÷ [72 × serum creatinine (mg/dL)]
- Females: 0.85 × male value
Critical warning: Even with dose adjustments, beta-lactams can cause neurotoxicity in renal impairment. One case report showed severe neurotoxicity with cefepime despite "appropriate" renal dosing 6. Monitor closely for confusion, myoclonus, or seizures, especially in elderly patients with reduced renal function.
Duration of Therapy
- Minimum: Continue for 48-72 hours after the patient becomes asymptomatic or shows bacterial eradication 1
- Standard: 5-10 days for uncomplicated pneumonia 1
- Do not use doses smaller than recommended even if clinical improvement occurs early 1
Key Clinical Considerations
Cefuroxime has limitations for CAP:
- The 2019 ATS/IDSA guidelines favor ceftriaxone (1-2 g daily) or cefotaxime (1-2 g every 8 hours) over cefuroxime for hospitalized CAP 2
- Recent data on ceftriaxone suggests 1 g daily may be sufficient in areas with low resistance, with lower C. difficile rates than 2 g daily 7
- Cefuroxime requires three-times-daily dosing versus once-daily ceftriaxone, affecting nursing workload and patient convenience
Microbiologic coverage: Cefuroxime covers S. pneumoniae, H. influenzae, and most common CAP pathogens 1, 8, with MIC ≤4 mcg/mL predicting 97% clinical success 8. However, it lacks atypical coverage, necessitating macrolide combination therapy.
Serum protein binding: Approximately 50% protein-bound 1, which is clinically relevant in hypoalbuminemic states where free drug concentrations may be higher.